Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EHA 2017 | The potential of momelotinib against myeloproliferative malignancies

Claire Harrison • 25 Aug 2017

EHA 2017

Myeloproliferative Neoplasms Momelotinib Ruxolitinib

SIMPLIFY-1 SIMPLIFY-2

Anemia remains an important, unsolved problem for patients suffering from myeloproliferative malignancies. Claire Harrison, MD, DM, FRCP, FRCPath from Guys and St Thomas’ NHS Foundation Trust, London, UK speaks to us about the potential importance of the drug momelotinib. Prof. Harrison discusses the interesting results of the Phase III clinical trials, SIMPLIFY 1 (NCT01969838) and 2 (NCT02101268) which compared momelotinib against ruxolitinib and Best Alternative Therapy. She also talks about her hopes for this drug in the future. This interview was recorded at the European Hematology Association (EHA) 2017 annual congress held in Madrid, Spain.

Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more

Claire Harrison et al. • 11 Dec 2023

The value of novel JAK2 and CALR-targeted therapies in MPNs

Claire Harrison • 24 Apr 2023

The role of transplantation in MPNs & factors to consider when selecting patients for transplant

Claire Harrison • 24 Apr 2023

Optimizing current treatment approaches in myelofibrosis

Claire Harrison • 24 Apr 2023

Related Videos

Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting

Alex Rampotas • 16 Apr 2024

JAK inhibitor combination therapy for the treatment of myelofibrosis

Ruben Mesa • 9 Dec 2023

XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF

John Mascarenhas • 10 Dec 2023

Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis

John Mascarenhas • 10 Dec 2023